Pyridostigmine
FDA Approved
Description
Pyridostigmine is an acetylcholinesterase inhibitor that enhances neuromuscular transmission. It is used in the management of oculomotor nerve palsies and other cranial nerve disorders to improve muscle strength and coordination. The medication has been employed in various neurological conditions affecting eye movement and motor control.
Indications & Therapeutic Use
Myasthenia gravis, oculomotor nerve palsy, neuromuscular transmission disorders
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pyridostigmine
| Generic Name | Pyridostigmine |
| Brands | 1 brand available |
| Active Ingredient | Pyridostigmine bromide |
| Drug Class | Myasthenia gravis |
| Manufacturer | Valeant Pharmaceuticals |
| Dosage Forms | Tablets 60mg; Extended-release tablets 180mg; Syrup 60mg/5mL |
| Medical Code | N07AA02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes